Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03294577
Other study ID # BPI-2358-106 phase 3
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date October 23, 2019
Est. completion date September 25, 2025

Study information

Verified date January 2021
Source BeyondSpring Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + combination plinabulin/pegfilgrastim Severe neutropenia is an absolute neutrophil count (ANC) <0.5 × 10^9/L. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.


Description:

This is a multi-center randomized study, double-blind phase 3 trial. Approximately 222 patients are planned to be enrolled in Phase 3. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study. These agents are among the most active and commonly used chemotherapeutic agents employed for treating patients with breast carcinoma. In particular, TAC chemotherapy has been used for the adjuvant treatment of HER2 negative early breast cancer patients with node positive disease as well as for node negative breast cancer patients who have a high risk of recurrence. Plinabulin is a novel small molecule that is being developed for the mitigation of chemotherapy-induced neutropenia. Administered by IV infusion on the same day of (approximately 1 hour after) chemotherapy (TAC), plinabulin will be given in a single dose per cycle. Plinabulin is being studied to see if it is a convenient alternative to G-CSF, pegfilgrastim, for the prevention of chemotherapy-induced neutropenia. In this trial, treatment will be double blinded, approximately 222 patients with breast cancer are expected to be enrolled. Patients are randomly assigned to one of the treatment arms, with 111 patients enrolled in each arm, with the arm designation and planned intervention as follows: Arm 1: TAC + pegfilgrastim (6.0 mg) + placebo matching plinabulin. Arm 2: TAC + pegfilgrastim (6.0 mg) + plinabulin (40 mg). Cycles 1 to 4 will consist of TAC (or TC for Cycles 2 to 4) administered IV on Day 1 every 21 days. Patients will receive a single dose of plinabulin or placebo IV over 30 minutes (±5 minutes) in a double blinded manner, 30 minutes after the end of the TAC (or TC for Cycles 2 to 4) infusion. On Day 2 of each cycle (≥24 hours after completing chemotherapy), all patients will receive a single dose of pegfilgrastim (6.0 mg). The long-term safety follow-up through patients contacts by phone calls, letters or electronic means; or medical records reviews will be conducted to all subjects approximately every 6 months up to 5 years to monitor long term safety of plinabulin.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 221
Est. completion date September 25, 2025
Est. primary completion date September 25, 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Women who are at least 18 years of age at the time of signing the informed consent form. 2. In the opinion of their treating oncology investigator, are candidates for at least 4 cycles of chemotherapy with TAC (docetaxel, doxorubicin, & cyclophosphamide). 3. Patients who are candidates for adjuvant or neoadjuvant TAC will meet all of the following criteria: - Biopsy-proven, early stage (Stage I and II) and Stage III breast cancer, and - Have had no prior chemotherapy. 4. Pathological confirmation of cancer is required. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Have life expectancy of 3 months or more. 7. Laboratory results provided by the central laboratory within 14 days prior to study drug administration within noted ranges, per study protocol (local laboratories may be accepted on a case by case basis after discussion with the medical monitor; however in this case central laboratories must also be taken within the screening time window) 8. Prothrombin time (PT) and International Normalized Ratio (INR) =1.5 × ULN, activated partial thromboplastin time (PTT) =1.5 × ULN, based on central laboratory results. 9. Women of childbearing potential have a negative pregnancy test at screening. Exclusion Criteria: 1. History of myelogenous leukemia, myelodysplastic syndrome, or sickle cell disease. 2. Use of strong CYP3A4, CYP2D6 or P-glycoprotein (P-gp) inhibitors and inducers, within 14 days of the first administration of study drug and for the duration of the study. 3. Received an investigational agent or tumor vaccine within 2 weeks before the first dose of study drug; patients must have recovered from toxicity of prior treatment and have no >Grade 1 Common Terminology Criteria for Adverse Events (CTCAE) (v4.03) treatment emergent adverse events (TEAE). 4. Receiving any concurrent anticancer therapies (including concomitant anti-HER2/neu agents such as trastuzumab [Herceptin®], trastuzumab emtansine [TDM 1, Kadcyla®], pertuzumab [Perjeta®], lapatinib [Tykerb®]). 5. Received a prior bone marrow or stem cell transplant. 6. Have a co-existing active infection or received systemic anti-infective treatment within 72 hours before the first dose of study drug. 7. Concurrent or prior radiation therapy within 4 weeks before the first dose of study drug. 8. Chronic use of filgrastim, pegfilgrastim, or any bioequivalent (biosimilar) for severe chronic neutropenia or other chronic neutropenia syndrome. 9. Presence of any serious or uncontrolled illness including, but not limited to: uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure unstable angina pectoris, uncontrolled cardiac arrhythmia, uncontrolled arterial thrombosis, symptomatic pulmonary embolism, and psychiatric illness that would limit compliance with study requirements or any other conditions that would preclude the patient from study treatment as per the discretion of the Investigator. 10. Significant cardiovascular history: - Cardiac ventricular dysfunction inhibiting the patient's ability to receive 4 cycles of doxorubicin. - History of myocardial infarction or ischemic heart disease within 1 year (within a window of up to 18 days less than 1 year) before first study drug administration - Uncontrolled arrhythmia - History of congenital QT prolongation - Electrocardiogram (ECG) findings consistent with active ischemic heart disease - New York Heart Association Class III or IV cardiac disease; - Uncontrolled hypertension: blood pressure consistently >150 mm Hg systolic and > 100 mm Hg diastolic in spite of antihypertensive medication 11. History of hemorrhagic diarrhea, inflammatory bowel disease, or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable). History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility. 12. Any other active malignancy requiring active therapy. 13. Known human immunodeficiency virus (HIV) seropositivity. 14. Active Hepatitis B virus (HBV) infection which requires antiviral treatment or the patient has detectable Hepatitis B surface Antigen (HBsAg); hepatitis B surface antibody (anti-HBs) without detectable HBsAg does not exclude patients from the study. Hepatitis C infection (Hepatitis C antibody reactive) which requires treatment also excludes patients from the study. 15. Female patient who is pregnant or lactating. 16. Use of prophylactic antibiotics. 17. Unwilling or unable to comply with procedures required in this protocol. 18. History of allergy to any of the study drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pegfilgrastim
PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Plinabulin
Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
Other:
D5W Placebo
Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
Drug:
Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.

Locations

Country Name City State
China China-Japan Union Hospital of Jilin University Tumor department of Hematology Changchun Jilin
China Cancer Center of Guangzhou Medical University Guangzhou Guangdong
China Cancer Center of Guangzhou Medical University Breast Oncology Guangzhou Guangzhou
China No. 1 Banshandong Road Hangzhou Gongshu District
China Harbin Medical University Cancer Hospital Harbin Harbin
China Liaoning Cancer Hospital & Institute Shenyang Shenyang
China Fourth Hospital of Hebei Medical University Breast cancer department Shijiazhuang Hebei
Ukraine Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department Dnepropetrovsk
Ukraine Prykarpatskiy Regional Oncological Center Ivano-Frankivs'k
Ukraine Regional Clinical Oncology Center Kharkiv
Ukraine V.T. Zaycev Institute Kharkiv
Ukraine Public Institution Kryvyi Rih Oncology Center Krivoy Bereg
Ukraine Kirovograd Regional Oncological Center Kropyvnytskyi
Ukraine Hemotherapy Department Kyiv
Ukraine Kyiv City Clinical Oncological Center Kyiv
Ukraine Lviv State Oncological Regional Lviv
Ukraine Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho Odessa
Ukraine Zakarpattia Regional Clinical Oncology Center Uzhgorod
Ukraine Vinnytsya Regional Clinical Oncology Dispensary Vinnytsia
Ukraine Zaporizhia Regional Clinical Oncology Dispensary Zaporizhzhya

Sponsors (1)

Lead Sponsor Collaborator
BeyondSpring Pharmaceuticals Inc.

Countries where clinical trial is conducted

China,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with Duration of Severe Neutropenia (DSN) =0 DSN is defined as Days of Grade 4 Neutropenia (ANC less than 0.5 X 109/L) Duration of Grade 4 neutropenia assessed during the first cycle (21 days)
Secondary Mean DSN assessment DSN is defined as Days of Grade 4 Neutropenia (ANC less than 0.5 X 109/L) From day 1 to day 8 in first cycle (21 days)
Secondary Mean ANC nadir record and evaluate the lowest ANC value Duration of first cycle (21 days)
Secondary Percentage of Patients without grade 3 and grade 4 neutropenia ANC less than 1 x 109/L and above 0.5x 109/L is defined as grade 3 neutropenia. ANC less than 0.5 X 109/L is defined as grade 4 neutropenia. Duration of first cycle (21 days)
Secondary Mean DSN assessment within 15 days To evaluate the effect of Plinabulin related to DSN within 15 days From day 1 to day 15 in the first cycle (21 days)
Secondary Average change in bone pain Record the bone pain score from the numerical rating scale (NRS) From -1 day over the observational period
Secondary Rate of composite risks Composite risks includes infection, FN, hospitalization, significant disability, life threatening and death Duration of all 4 cycle (21 days)
Secondary Percentage of patients with relative dose intensity < 85% Assess the percentage of patients with RDI < 85% Duration of all 4 cycle (21 days)
See also
  Status Clinical Trial Phase
Completed NCT02643901 - Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects Phase 1
Terminated NCT02454530 - Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
Completed NCT02251977 - Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer Phase 3
Active, not recruiting NCT02104830 - Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients Phase 3
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Not yet recruiting NCT03701841 - Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis
Completed NCT00776165 - Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF) Phase 3
Completed NCT03251768 - Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients Phase 2
Recruiting NCT04101760 - Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Phase 3
Completed NCT04134429 - Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
Completed NCT04227990 - Plinabulin iv Solution in Prevention of TAC Induced Neutropenia Phase 2
Completed NCT03102606 - Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 Phase 3
Completed NCT01569087 - Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients Phase 2
Completed NCT05512676 - Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
Completed NCT04460079 - Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
Recruiting NCT02725606 - Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer Phase 1
Completed NCT02692742 - Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia Phase 2
Completed NCT02532712 - Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers Phase 1
Completed NCT01516736 - Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim Phase 3
Terminated NCT04887831 - Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab Phase 2